argenx Is Printing Money and the Market Is Still Sleeping On It

Signal: BUY | Score: 63.73/100

argenx just posted one of the cleanest earnings beats in biotech this year, revenue is growing at 60% year-over-year, and the stock is still sitting 12% below analyst consensus price targets. At $1,044, this is a rare case where the fundamentals are accelerating faster than the stock price.

The Setup

ARGX is trading at $1,044, just off its 52-week high of $1,058. That's not a red flag - that's a stock consolidating near all-time highs after a massive run from $658. The momentum score of 79 out of 100 tells you the trend is intact. RSI sits at 73.9, which is technically overbought territory, but in strong momentum names like this, overbought conditions can persist for months. The stock has basically doubled off its 52-week low, and the price action is constructive. This looks like trend continuation, not a tired rally.

The Catalyst

The Q2 2026 earnings report on July 21-23 was the trigger. argenx posted EPS of $7.32 against a consensus of $5.86 - a 25% beat. Revenue came in at $1.54B versus the $1.45B expected, with $1.5B in global product net sales up 60% year-over-year. That is not a rounding error. That is a company firing on every cylinder.

Then there's the May 10, 2026 FDA approval expanding VYVGART's U.S. label to cover seronegative generalized myasthenia gravis - a meaningful patient population that was previously excluded. Add in 18 consecutive quarters of growth across MG and CIDP with a pipeline that spans neurology, rheumatology, and kidney disease, and you have a compounding growth story that is nowhere near its ceiling. Next earnings are October 22, giving this trade a clean 62-day runway before the next major event.

Bull Case

Analyst consensus target sits at $1,172, representing roughly 12% upside from current levels with strong institutional backing
Revenue growing at 59% year-over-year with a 32% profit margin - this company has figured out how to scale profitably, which is rare in biotech
Forward P/E of 26.6x is reasonable for a company with 92% earnings growth - the PEG of 1.63 is not egregious for this quality level

Bear Case

RSI above 73 means any broad market selloff could create a sharp short-term pullback before the next leg higher
Price-to-book of 193x is elevated and leaves little room for execution missteps going into Q3 earnings

The Trade

Entry: $1,044
Target: $1,172 (analyst consensus)
Stop Loss: $970 (roughly 7% downside, below recent consolidation)
Risk/Reward: approximately 1.7:1
Timeframe: 60-90 days into Q3 earnings

*This is one person's analysis, not financial advice. Always do your own research.*